Home>>Signaling Pathways>> GPCR/G protein>> Cannabinoid Receptor>>O-1821
O-1821 Catalog No.GC17699

cannabidiol analog with close structural similarity to O-1918 which is a selective antagonist of abnormal cannabidiol

Size Price Stock Qty
In stock
In stock
In stock
In stock

Customer Review

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & SDS

View current batch:

Chemical Properties

Cas No. 35482-50-9 SDF
Chemical Name 5-methyl-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-1,3-benzenediol
Canonical SMILES CC1=C[C@@H](C2=C(O)C=C(C)C=C2O)[C@H](C(C)=C)CC1
Formula C17H22O2 M.Wt 258.4
Solubility ≤30mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
  • Molarity Calculator

  • Dilution Calculator

**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).



O-1821 is an cannabidiol analog with similar structure to O-1918, a selective antagonist of abnormal cannabidiol.

Abnormal cannabidiol, a synthetic regioisomer of cannabidiol, fails to elicit either central cannabinoid (CB1) or peripheral cannabinoid (CB2) receptors and is lack of psychotropic activity. It can induce endothelium-dependent vasodilation through a CB1/CB2/nitric oxide-independent mechanism.

In vitro: O-1821 is a cannabidiol analog with similar structure to O-1918, which was identified as a selective antagonist of abnormal cannabidiol at the non-central cannabinoid (CB1)/peripheral cannabinoid (CB2) receptors endothelial receptor. It was found that O-1918 could not bind to CB1 or CB2 receptors and thus could not cause vasorelaxation at concentrations up to 30 μM, but it could cause concentration-dependent inhibition of the vasorelaxant effects of abn-cbd and anandamide. Moreover, in human umbilical vein endothelial cells, abn-cbd was able to induce phosphorylation of p42/44 mitogenactivated protein kinase and protein kinase B/Akt, which could be inhibited by O-1918 or by phosphatidylinositol 3 (PI3) kinase inhibitors [1].

In vivo: O-1918 was found to be able to inhibit the hypotensive effect of abn-cbd dose-dependently but not the hypotensive effect of the CB1 receptor agonist (-)-11-OH-Δ9-tetrahydrocannabinol dimethylheptyl in anesthetized mice [1].

Clinical trial: So far, no clinical study has been conducted.

[1] Offertáler, L. ,Mo, F.M.,Bátkai, S., et al. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Molecular Pharmacology 63(3), 699-705 (2003).